Innate Pharma SA
- Last sale
- Nov 12, 2026 · -5.66%
- Market cap
- $140.58M
- 93.72M shares
- Filings
- 340
FY 2025−55.2% FY25 yoy
FY 2025N/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025−57.7% FY25 yoy
- $140.58M
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | €9,005,000 | reported | |
| FY 2024 | 2024-12-31 | €20,121,000 | reported | |
| FY 2023 | 2023-12-31 | €61,641,000 | reported | |
| FY 2022 | 2022-12-31 | €57,674,000 | reported | |
| FY 2021 | 2021-12-31 | €24,703,000 | reported | |
| FY 2020 | 2020-12-31 | €69,773,000 revised | reported | |
| FY 2019 | 2019-12-31 | €85,449,000 revised | reported | |
| FY 2018 | 2018-12-31 | €93,952,000 | reported | |
| FY 2017 | 2017-12-31 | €44,033,000 | reported |
Biological products, except diagnostic substances
Innate Pharma SA is the 104th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
FATEFate Therapeutics Inc$6.6M51.2%2,051.1%$161.7MSTROSutro Biopharma, Inc.$102.5M65.2%186.5%$159.0MENGNenGene Therapeutics Inc.———$153.5MCMPXCompass Therapeutics, Inc.$0.0100.0%—$147.1MTARAProtara Therapeutics, Inc.———$143.0MARMPArmata Pharmaceuticals, Inc.———$141.3M
IPHAInnate Pharma SA (this company)———$140.6M
MOLNMolecular Partners AG———$139.7MLENZLENZ Therapeutics, Inc.$19.1M—430.3%$127.9MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Innate Pharma SA · CIK 1598599 · Engraved from SEC EDGAR